DTX Pharma

ARTHEx Biotech

This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.

Shape Therapeutics

The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.

Entrada Therapeutics

This biopharmaceutical company develops intracellular medicines for patients with neuromuscular and rare diseases using its proprietary endosomal escape vehicle delivery platform.

Evox Therapeutics

This biotechnology company develops engineered exosome therapeutics to deliver genetic medicines and proteins for patients with rare diseases and neurological disorders.

Epitome Therapeutics

This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.

Northsea Therapeutics

This company develops structurally engineered fatty acid drugs for patients with metabolic, inflammatory, and fibrotic diseases such as rare liver disorders.

Replay Therapeutics

This biotech company develops genome writing and delivery platforms to provide genetic medicines for patients with rare skin, eye and haematological diseases.

ADARx Pharmaceuticals

This clinical-stage biotechnology company develops RNA-targeting therapeutics for patients with genetic, cardiometabolic, complement-mediated, and central nervous system diseases.